Recombinant human Akt1 protein

AKT1, also known as RAC-alpha serine/threonine-protein kinase, is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Recombinant human AKT1, fused to His-tag at C-terminus, was expressed in insect cell and purified by using conventional chromatography techniques.

Product Specifications

Product Name Alternative

Protein kinase B, Protein kinase B alpha, Proto-oncogene c-Akt, RAC-PK-alpha

Expression System

Baculovirus

Antigen Species

Human

Tag

His-Tag

Applications

SDS-PAGE

Concentration

0.5 mg/mL (determined by absorbance at 280 nm)

Endotoxin

< 1 EU per 1ug of protein (determined by LAL method)

Purity

> 90% by SDS-PAGE

Molecular Weight

56.7 kDa (488aa)

Additionnal Information

Akt1, ATGP3118-10 µg, ATGP3118-20 µg, ATGP3118-50 µg, ATGP3118-100 µg, ATGP3118-250 µg, ATGP3118-500 µg, ATGP3118-1 mg, ATGP3118-10, ATGP3118-20, ATGP3118-50, ATGP3118-100, ATGP3118-250, ATGP3118-500, ATGP3118-1

References & Citations

Lindhurst MJ, et al (2011) N Engl J Med. 365 (7) :611-9.

Other References

Wang Q, et al. Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma. (Oncogene. 2017) {https://pubmed.ncbi.nlm.nih.gov/28692058/}